Thoratec, Abiomed, ACC Comment On CMS Revision Of VAD Coverage Policy
This article was originally published in The Gray Sheet
Executive Summary
Ventricular assist device maker Thoratec is hesitant to support a procedure-experience threshold as a criterion for CMS clearance of facilities implanting VADs for destination therapy
You may also be interested in...
Who Should Perform VAD Destination Therapy? CMS Proposes Changes
CMS issued a proposed national coverage decision 1memo Dec. 27 that would revise the medical facility criteria for implanting ventricular assist devices for extended support of patients ineligible for a heart transplant
Who Should Perform VAD Destination Therapy? CMS Proposes Changes
CMS issued a proposed national coverage decision 1memo Dec. 27 that would revise the medical facility criteria for implanting ventricular assist devices for extended support of patients ineligible for a heart transplant
Thoratec Projects Market Growth As CMS Revamps VAD Coverage Criteria
Thoratec anticipates that the market for HeartMate will expand if CMS revises its standards for facilities that implant ventricular assist devices (VAD) as a destination therapy, a company official said